AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares decreased by 1.11%, Oclaro, Inc. (NASDAQ:OCLR)

Posted by Samantha Donahue May 29, 2013 0 Comment 853 views


Hartford, CT 05/29/2013 (GDPInsider) – AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares closed at $2.68 dropped by 1.11% (-$0.03) compared to previous day’s close of about $2.71. It touched a high of $2.72 and low of $2.63 during the day. It is about 80.93% below its 52 week high of $14.08 and about 19.33% above its 52-week low of $2.25. Around 0.902 million Shares have exchanged hands during last trading session which is lower as compared to average shares changed during a period of 30 days which is 3.66 million. The market capitalization of the company is $139.19 million. The earnings per share of the company are -$2.56 which shows that the company is incurring losses. The average true range of the stock is 0.40. The high current ratio of the company 2.47 shows good capital working capital management. The beta of the company is 0.86.

There is some bad news for AVEO Pharmaceuticals because Astelles said Aveo that it will not allow funding of additional studies for the drug used in renal cancer. This has led to the setback of Aveo.

Is AVEO a solid investment at these levels? Get valuable updates and exclusive insights here.

Oclaro, Inc. (NASDAQ:OCLR) shares closed at $1.07 dropped by 1.87% (-$0.02) compared to previous day’s close of about $1.07. It touched a high of $1.07 and low of $1.05 during the day. It is about 66.85% below its 52 week high of $3.19 and about 6.82% above its 52-week low of $0.99. Around 0.583 million Shares have exchanged hands during last trading session which is lower as compared to average shares changed during a period of 30 days which is 0.947 million. The market capitalization of the company is $97.97 million. The earnings per share of the company are -$0.79 which shows that the company is incurring losses. The average true range of the stock is 0.06. The high current ratio of the company 1.55 shows good capital working capital management. The beta of the company is 3.54.

How Should Investors Trade OCLR Now? Get key and important information right here.

Disclosure:

WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.


About Samantha Donahue

Samantha Donahue is a digital fellow with GDP insider. Samantha earned a Bachelor's degree in Government from Cornell University and later his Master's degree in Journalism from Columbia University. She has also received numerous awards from the Associated Press, Society of Professional Journalists, and other media organizations for many of her exclusive stories. Samantha thrives reporting on breaking news and as a general assignments news reporter.

View all post by Samantha Donahue Visit author's website

Write Your Comment